Tandem Diabetes Care, Inc.

As of June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh carries a market capitalization of 5.51B, placing it among publicly traded companies globally. Its enterprise value stands at 6.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh has 1.04B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.00, and the price-to-book ratio stands at 8.17.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.97B versus a market cap of 5.51B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh maintains a current ratio of 3.18, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 566.96, indicating elevated leverage, while an interest coverage ratio of -4.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh posted a negative return on equity (ROE) of -48.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.24, reflecting losses generated across the asset base. The company generates approximately 2.12M in revenue per employee across its workforce of 2,537.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.30 indicates how many times Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh recorded 11.99M in income tax expense. The company reported a pretax loss of -315.29M and -327.28M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh's stock has gained approximately 9.98% over the past 52 weeks. The 50-day moving average sits at 6.39, while the 200-day moving average is 6.34.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh generated 5.38B in revenue and converted that into -327.28M in net income, yielding earnings per share of -0.32. EBITDA reached -143.87M, while operating income came in at -236.71M.

As of June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh holds 2.36B in cash and equivalents against 3.82B in total debt, resulting in a net debt position of 2.79B. Total book value stands at 673.98M, with working capital of 2.85B providing operational flexibility.

Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh produced -28.55M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -290.60M in capital expenditures, free cash flow totaled -319.14M - equivalent to -0.31 per share.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh posted a gross margin of 56.01, reflecting its pricing power and cost economics. The operating margin of -4.40 and net profit margin of -6.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -26.03, meaning Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh has an Altman Z-Score of 0.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.